Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTB41 plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for driver-negative advanced non-small cell lung cancer
CTR20261510Phase 2Active
- Sponsor
- Sinocelltech Group Limited
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SCTB41, tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Sinocelltech Group Limited. Started May 2026; status: active.
02
Drugs
SCTB41tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20261510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261510.